<DOC>
	<DOCNO>NCT00004244</DOCNO>
	<brief_summary>This phase I trial study side effect best dose interleukin-12 interferon alfa treat patient metastatic kidney cancer malignant melanoma . Interleukin-12 may kill tumor cell stop blood flow tumor stimulate person 's white blood cell kill cancer cell . Interferon alfa may interfere growth cancer cell . Combining interleukin-12 interferon alfa may kill cancer cell .</brief_summary>
	<brief_title>Interleukin-12 Interferon Alfa Treating Patients With Metastatic Kidney Cancer Malignant Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity interleukin-12 interferon alfa patient metastatic renal cell carcinoma malignant melanoma . II . Determine maximum tolerate dose drug concurrently administer patient population . III . Obtain preliminary data antitumor efficacy combination patient . OUTLINE : This dose-escalation study , follow randomize study . Patients receive interleukin-12 subcutaneously ( SC ) twice week interferon alfa SC three time week every week 4 week . Treatment continue absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos interleukin-12 interferon alfa maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Once MTD establish , additional patient accrue randomized 1 follow treatment arm : ARM I : Patients receive interleukin-12 SC twice week 2 week , follow treatment interleukin-12 combination interferon alfa describe . ARM II : Patients receive interferon alfa SC three time week 2 week , follow treatment interleukin-12 combination interferon alfa describe . ARM III : Patients receive treatment interleukin-12 combination interferon alfa MTD describe . PROJECTED ACCRUAL : A total 20-30 patient accrue dose escalation portion study . An additional 18 patient ( 5 arm I , 5 arm II , 8 arm III ) accrue randomize portion study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm renal cell carcinoma malignant melanoma Strong clinical evidence biopsy proof metastases site site distant primary tumor Bidimensionally measurable evaluable disease No significant effusion and/or ascites No 3 prior regimens metastatic disease No known CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.5 g/dL Hepatic : Bilirubin great 1.5 mg/dL ALT/AST great 3 time upper limit normal Renal : Creatinine great 1.8 mg/dL Calcium great 11.5 mg/dL Cardiovascular : No history serious cardiac arrhythmia cardiac arrhythmia require treatment No congestive heart failure No angina pectoris No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active peptic ulcer No autoimmune disease No inflammatory bowel disease No local systemic infection require IV antibiotic within past 28 day No known seizure disorder No prior malignancy except basal cell squamous cell skin cancer , carcinoma situ cervix , curatively treated malignancy complete remission least 3 year HIV , hepatitis B surface antigen , hepatitis C negative PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered prior biologic therapy Chemotherapy : Recovered prior chemotherapy Endocrine therapy : At least 28 day since prior hormonal therapy recover No concurrent corticosteroid except replacement steroid Radiotherapy : Recovered prior radiotherapy At least 28 day since prior radiotherapy control pain skeletal lesion Surgery : At least 28 day since prior major surgery require general anesthesia No organ allografts Other : No concurrent aspirin No concurrent barbiturates No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>